Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.

Abstract

With currently available combination chemotherapy regimens, the outcome of the patients newly diagnosed with aggressive non-Hodgkin's lymphoma (NHL) identified as 'high' and 'high-intermediate' risk groups according to the international prognostic index (IPI) is still unsatisfactory and a more innovative therapy is urgently required to improve the survival… (More)

Topics

Cite this paper

@article{Intragumtornchai2006RituximabCHOPESHAPVC, title={Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.}, author={Tanin Intragumtornchai and Udomsak Bunworasate and Thanyaphong Na Nakorn and Ponlapat Rojnuckarin}, journal={Leukemia & lymphoma}, year={2006}, volume={47 7}, pages={1306-14} }